Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals Inc before investing.

In this article, we go over a few key elements for understanding Recursion Pharmaceuticals Inc’s stock price such as:

• Recursion Pharmaceuticals Inc’s current stock price and volume
• Why Recursion Pharmaceuticals Inc’s stock price changed recently
• Upgrades and downgrades for RXRX from analysts
• RXRX’s stock price momentum as measured by its relative strength

About Recursion Pharmaceuticals Inc (RXRX)

Before we jump into Recursion Pharmaceuticals Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Want to learn more about Recursion Pharmaceuticals Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals Inc’s Stock Price as of Market Close

As of September 06, 2024, 4:00 PM, CST, Recursion Pharmaceuticals Inc’s stock price was $5.92.

Recursion Pharmaceuticals Inc is down 4.05% from its previous closing price of $6.17.

During the last market session, Recursion Pharmaceuticals Inc’s stock traded between $6.04 and $6.33. Currently, there are 242.20 million shares of Recursion Pharmaceuticals Inc stock available for purchase.

Unfortunately, Recursion Pharmaceuticals Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Recursion Pharmaceuticals Inc Stock Price History

Recursion Pharmaceuticals Inc’s (RXRX) price is currently down 18.68% so far this month.

During the month of September, Recursion Pharmaceuticals Inc’s stock price has reached a high of $6.78 and a low of $5.89.

Over the last year, Recursion Pharmaceuticals Inc has hit prices as high as $15.74 and as low as $4.97. Year to date, Recursion Pharmaceuticals Inc’s stock is down 23.22%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Recursion Pharmaceuticals Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 05, 2024, there were 0 analysts who downgraded Recursion Pharmaceuticals Inc’s stock and 5 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Recursion Pharmaceuticals Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Recursion Pharmaceuticals Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Recursion Pharmaceuticals Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Recursion Pharmaceuticals Inc (RXRX) by visiting AAII Stock Evaluator.

Relative Price Strength of Recursion Pharmaceuticals Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 05, 2024, Recursion Pharmaceuticals Inc has a weighted four-quarter relative price strength of -14.61%, which translates to a Momentum Score of 24 and is considered to be Weak.

Want to learn more about how Recursion Pharmaceuticals Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Recursion Pharmaceuticals Inc Stock Price: Bottom Line

As of September 6, 2024, Recursion Pharmaceuticals Inc’s stock price is $5.92, which is down 4.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Recursion Pharmaceuticals Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.